Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$37.15

-0.49 (-1.30%)

, BMY

Bristol-Myers

$57.50

(0.00%)

07:04
10/13/18
10/13
07:04
10/13/18
07:04

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration with this weekly recap compiled by The Fly: 1. FEDERAL RESERVE: President Trump once again criticized the Federal Reserve for lowering interest rates following a big market selloff, being quoted as stating, "The Fed has gone crazy" and that the central bank "is too tight." In an interview with Fox News on Wednesday night, Trump added that the Fed "is going loco and there is no reason for them to do it." 2. TRUMP-XI MEETING: U.S. President Donald Trump and Chinese President Xi Jinping have agreed to meet next month at the G-20 summit in Buenos Aires at the end of November to discuss the trade conflict that has grown more intense, according to The Washington Post, citing three people briefed on the arrangement. 3. DRUG PRICE TRANSPARENCY: President Donald Trump is set to sign two measures of legislation into law that are aiming to make drug prices more transparent, according to CNN. The Lowest Price Act and the Patient Right to Know Drug Prices Act "aim to end the drug industry's so-called gag orders of pharmacists, which prevent them from discussing cheaper price options with consumers," added CNN. Publicly traded drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). 4. NEW YORK TIMES: JPMorgan analyst Alexia Quadrani raised her price target on New York Times (NYT) shares earlier this week to $32 from $27, citing ongoing digital subscriber growth as the "Trump bump" continues. Looking at results for the second half of the year, Quadrani projects a ramp in digital subscriber growth in part driven by the Kavanaugh hearings, Trump tax stories, and midterm elections. Additionally, the analyst noted that she believes churn remains relatively low. Since taking office, President Donald Trump has been very critical of the New York Times and many of its media peers, frequently using the term "fake news" to deride their reporting. 5. USPS PRICE HIKE: Shares of Stamps.com (STMP) jumped on Thursday after the U.S. Postal Service proposed the biggest price jump on stamps in its history. Facing pressure from President Trump and his administration, USPS is looking to raise the price of 1-oz. letters to 55c from 50c. If approved by regulators, the Postal Service is said to plan to also increase the shipping service cost used by Amazon (AMZN) by 9%-12%, just months after President Donald Trump criticized USPS for giving too good of a deal to the e-commerce giant. "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

AZN

AstraZeneca

$37.15

-0.49 (-1.30%)

BMY

Bristol-Myers

$57.50

(0.00%)

LLY

Eli Lilly

$110.49

2.54 (2.35%)

GSK

GlaxoSmithKline

$38.31

-0.17 (-0.44%)

JNJ

Johnson & Johnson

$133.78

-0.03 (-0.02%)

MRK

Merck

$69.77

1.41 (2.06%)

NVS

Novartis

$82.77

0.56 (0.68%)

PFE

Pfizer

$43.78

0.97 (2.27%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$42.89

-0.83 (-1.90%)

NYT

New York Times

$24.98

0.145 (0.58%)

STMP

Stamps.com

$214.32

-0.43 (-0.20%)

AMZN

Amazon.com

$1,788.63

69.51 (4.04%)

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 24

    Dec

  • 11

    Jan

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

  • 28

    Apr

AZN AstraZeneca
$37.15

-0.49 (-1.30%)

09/06/18
HCWC
09/06/18
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright impressed by Checkpoint Therapeutics' first clinical data
H.C. Wainwright analyst Joseph Pantginis says Checkpoint Therapeutics' (CKPT) first clinical data in its history "did not disappoint." The data show a "significant clinical benefit" from CK-101 treatment, Pantginis tells investors in a research note. With these safety and efficacy data in hand, Checkpoint's CK-101 may show competitive clinical advantages versus approved EGFR therapies, including AstraZeneca's Tagrisso, at least in the non-small-cell lung carcinoma indication, the analyst contends. He's "impressed" with the data and notes that Checkpoint management has confirmed its intention to move into a pivotal study in 2019 mimicking the Tagrisso Flaura study. Pantginis has a Buy rating on Checkpoint Therapeutics with an $11 price target.
09/14/18
ROTH
09/14/18
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains bullish on Stemline after AstraZeneca's Lumoxiti approved
Roth Capital analyst Jotin Marango said he had viewed the BLA review for AstraZeneca's (AZN) Lumoxiti for Hairy Cell Leukemia as a relative gauge of what might happen with Stemline's (STML) Elzonris given what he sees as the similarities between the agents. Lumoxiti's approval makes him more bullish on Stemline ahead of the Q1 of 2019 PDUFA date for Elzonris, said Marango, who raised his assumed probability of success for its BLA to 90% from 75%. He raised his price target on Stemline shares to $33 from $30 and keeps a Buy rating on the stock.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Buy
AstraZeneca initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started AstraZeneca with a Buy rating and 7,018p price target, citing his belief that the company's new product launches in oncology and severe asthma can drive the fastest sales and EPS growth in global pharma.
09/17/18
PIPR
09/17/18
NO CHANGE
Target $35
PIPR
Neutral
Piper sees Astra's Lynparza as 'much cleaner' than Tesaro's Zejula
Piper Jaffray analyst Christopher Raymond reiterates a Neutral rating and $35 price target on Tesaro (TSRO) after analyzing a year's worth of adverse event reporting as captured by FDA's Adverse Event Reporting System database, which he obtained through a Freedom of Information Act request. The analyst, while cautioning that the database "likely contains inaccuracies and is far from perfect," is "struck by how much cleaner" AstraZeneca's (AZN) Lynparza appears versus Tesaro's Zejula and Clovis Oncology's (CLVS) Rubraca. Further, Raymond is also surprised that Zejula's adverse events rates do not appear to have decreased in any meaningful way year-over-year, despite Tesaro's active down-dosing efforts. Since the analyst thinks PARPi differentiation remains largely around safety, he lowered his Zejula estimates in 2019 and beyond. Lynparza is likely to maintain the upper hand, Raymond tells investors in a research note.
BMY Bristol-Myers
$57.50

(0.00%)

08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/08/18
GUGG
10/08/18
INITIATION
Target $70
GUGG
Neutral
Bristol-Myers initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Bristol-Myers with a Neutral rating and $70 price target, contending that near-term Opdivo catalysts are largely in the stock. He sees the risk-reward as being balanced ahead of several trial read outs in 2019 from Bristol and its competitors, Fernandez added.
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
LLY Eli Lilly
$110.49

2.54 (2.35%)

10/08/18
GUGG
10/08/18
INITIATION
Target $132
GUGG
Buy
Eli Lilly initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started Eli Lilly with a Buy rating and $132 price target, calling out the company's "Impressive execution as the industry's leading fast-follower." He sees limited downside from current levels with the potential for revaluation around the Phase 3 study readout for tanezumab.
10/08/18
10/08/18
DOWNGRADE

Neutral
Novo Nordisk downgraded to Neutral on Eli Lilly competition at BofA/Merrill
As previously reported, BofA Merrill Lynch analyst Sachin Jain downgraded Novo Nordisk (NVO) to Neutral from Buy after he lowered his Ozempic forecasts beyond FY23 to account for possible competitive pressure from Eli Lilly's (LLY) GIP/GLP-1. While he does not see competitive pressure on Novo's Ozempic until FY23, he still sees that threat as a sufficient overhang given that the injectable GLP-1 franchise accounts for about 40% of his Novo growth forecast from FY19-23E and about 30% for FY23, Sachin tells investors. He lowered his price target on Novo shares to DKK305 from DKK380.
10/12/18
CHLM
10/12/18
INITIATION
Target $33
CHLM
Hold
Elanco initiated with a Hold at Craig-Hallum
Craig-Hallum analyst Kevin Ellich initiated Elanco Animal Health (ELAN) with a Hold rating and $33 price target. While Elanco is well positioned to expand gross margin by about 10 percentage points over the next five years which will drive mid-teens operating income growth and Ellich likes the company's focus on pet therapeutics and disease prevention as well as food animal future protein and health, he believes shares are fairly valued trading at ~19x FY20 EV/EBITDA, which is an 8% premium to industry leader Zoetis (ZTS). With shares up 35% from the September 19 IPO price of $24, the analyst tells investors in a research note that he looks to get more positive on pullbacks, improved liquidity as Eli Lilly (LLY) still owns 80% of Elanco stock, and improved visibility on longer-term growth drivers that could lead to upside to his projections.
10/05/18
10/05/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. HP CUT TO NEUTRAL AT JPMORGAN: JPMorgan analyst Paul Coster downgraded HP Inc. (HPQ) to Neutral from Overweight while raising his price target for the shares to $29 from $28. Despite the company's "excellent execution," the shares have limited catalysts ahead, Coster told investors in a research note following the company's analyst day. The analyst recommended investors take profits with the stock up 24% year-to-date. HP shares were lower by 1.9% to $25.91 in late morning trading. ELI LILLY UPGRADED TO OUTPERFORM AT BMO: BMO Capital analyst Alex Arfaei upgraded Eli Lilly (LLY) to Outperform from Market Perform and raised his price target on the shares to $130 from $107. The analyst cited the prospects of LY3298176, a GIP and GLP-1 dual receptor agonist presented at EASD 54th Annual Meeting, which he believes "meaningfully improves" the company's long-term growth prospects. Arfaei sees "continued strong growth of the GLP-1 class" and anticipates an annualized revenue growth of about 15% through 2027, adding that he is also positive on Eli Lilly's margins and its other indications in fields such as obesity. Eli Lilly shares were higher by 1.8% to $115.01 in late morning trading. PEPSI CUT TO NEUTRAL AT MACQUARIE: Macquarie analyst Caroline Levy downgraded Pepsi (PEP) to Neutral from Outperform and cut its price target to $107 from $122 following the company's Q3 report. Levy noted that Pepsi reported solid Q3 organic sales growth of 5%, but EBIT margins fell do to increased brand spending, higher input costs abroad due to FX hikes, and higher freight. The analyst said she expects these pressures to remain a drag on margins and cut estimates to reflect dilution from the Sodastream acquisition, tougher comps, and lack of tax reform benefits. Further, Levy expects organic sales growth will require more investment while costs continue to climb. ROKU STARTED WITH A NEUTRAL AT WEDBUSH: Wedbush analyst Michael Pachter initiated Roku (ROKU) with a Neutral rating and $73 price target. While Roku has built an "exceptional" platform on the back of its players and is positioning itself as the best-in-class option for OTT advertising, Roku's growth is fully priced into its share price, Pachter told investors in a research note. The analyst believes that any pullback may provide an opportunity to build a position. SUPER MICRO COMPUTER CUT TO HOLD AT MAXIM: Maxim analyst Nehal Chokshi downgraded Super Micro Computer (SMCI) to Hold from Buy. The analyst stated that while the Bloomberg Businessweek article alleging the company's "servers sold to customers contained malicious microchips" were strongly refuted, the detail, the reputable nature of the source, and the number of cross reference checks lend to its credibility. Chokshi further noted that the company's ongoing delay in releasing its 2017 10K filing adds to his concerns, stating that he no longer sees reward relative to risk as asymmetric. Super Micro Computer shares were higher by 3.1% to $12.99 in late morning trading.
GSK GlaxoSmithKline
$38.31

-0.17 (-0.44%)

10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
GlaxoSmithKline initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started GlaxoSmithKline with a Neutral rating and 1,679p price target, stating that he views its upside more in the consumer side than in pharma. The company's oncology and immunology pipeline could emerge, but it is still a bit early to tell, Fernandez added in his initiation note.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
08/30/18
08/30/18
DOWNGRADE

GlaxoSmithKline downgraded to Hold from Buy at Liberum
Liberum analyst Roger Franklin downgraded GlaxoSmithKline to Hold while raising his price target for the shares to GBP 17 from GBP 16.30. The analyst believes the company's improved research and development is now priced into the shares and he sees less upside going forward.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
JNJ Johnson & Johnson
$133.78

-0.03 (-0.02%)

10/03/18
WBLR
10/03/18
NO CHANGE
WBLR
Outperform
Janssen termination inconsequential for Aduro Biotech, says William Blair
William Blair analyst Matt Phipps attributes the 13% pullback yesterday in shares of Aduro Biotech (ADRO) to the termination of the company's collaboration with Johnson & Johnson's (JNJ) Janssen Biotech. Janssen officially ended a license agreement for two strains of Aduro's engineered Listeria therapy for lung and prostate cancers. Based on prior data with the Listeria strains and Aduro's decision to discontinue internal development of this platform at the end of 2017, Janssen's decision is not surprising, Phipps tells investors in a research note. The analyst views the news as inconsequential for Aduro and notes he did not consider the program a driver of Aduro valuation. The analyst did not include any aspect of the program in his estimates for Aduro and keeps an Outperform rating on the shares.
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
10/04/18
CANT
10/04/18
NO CHANGE
Target $24
CANT
Overweight
Arrowhead price target raised to $24 from $18 at Cantor Fitzgerald
Cantor Fitzgerald analyst Justin Kim raised his price target for Arrowhead (ARWR) to $24 from $18 following a newly announced collaboration and license agreement with Johnson & Johnson's (JNJ) subsidiary Janssen. Overall, the analyst feels the agreement is positive for the company as the support of a large partner could speed up the development timelines, increase market penetration with expertise, and validates the TRiM platform that Arrowhead uses. The additional cash will support Arrowhead's internal clinical development, he adds. Kim reiterates an Overweight rating on Arrowhead's shares.
10/04/18
PIPR
10/04/18
NO CHANGE
Target $25
PIPR
Overweight
Arrowhead price target raised to $25 from $17 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead (ARWR) to $25 from $17 after the company signed a license and collaboration agreement with Johnson & Johnson's (JNJ) Janssen Pharmaceuticals to develop and commercialize ARO-HBV and up to 3 new TRiM candidates. The analyst notes that Arrowhead will receive $175M cash up front, a $75M equity investment, up to $3.5B in milestones plus up to mid-teens royalties on ARO-HBV. Tenthoff views this deal as transformative for Arrowhead, dramatically strengthening the balance sheet and finding a strong partner for ARO-HBV, while retaining the rest of TRiM pipeline. He reiterates an Overweight rating on Arrowhead's shares.
MRK Merck
$69.77

1.41 (2.06%)

10/11/18
FBCO
10/11/18
NO CHANGE
Target $81
FBCO
Outperform
Merck price target raised to $81 from $71 at Credit Suisse
Credit Suisse analyst Vamil Divan raised his price target for Merck to $81 from $71, while reiterating an Outperform rating on the shares. While the shares have had a significant move this year, the analyst sees room for additional upside as the company continues to roll out Keytruda, most notably in the 1st line non-small cell lung setting. However, Divan also acknowledges longer-term investors remain concerned about how the company will navigate the Januvia patent expiration in mid-2022.
10/08/18
GUGG
10/08/18
INITIATION
Target $84
GUGG
Buy
Merck initiated with a Buy at Guggenheim
Guggenheim analyst Seamus Fernandez started Merck with a Buy rating and $84 price target, citing the sales and EPS upside he sees as Keytruda growth expands in the U.S. and globally. He also sees some partner products, such as Lynparza and Lenvima, along with the company's pipeline as being underappreciated, Fernandez tells investors.
10/03/18
HCWC
10/03/18
NO CHANGE
Target $4
HCWC
Buy
H.C. Wainwright positive on BioLineRx economic stake increase in BL-8040
H.C. Wainwright analyst Joseph Pantginis notes that BioLineRx (BLRX) announced the increase of its economic stake in BL-8040 from 60% to 80% from Biokine Therapeutics. The analyst believes that this transaction should signal increased confidence to investors as to the company's increased investment into BL-8040. Additionally, Pantginis argues that COMBAT data at ESMO later this month represents a potential tipping point for shares. COMBAT is a Phase 2a open-label study evaluating the safety and efficacy of BL-8040 in combination with pembrolizumab in patients with advanced pancreatic cancer in collaboration with Merck (MRK). He reiterates a Buy rating and $4 price target on BioLineRx shares.
08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
NVS Novartis
$82.77

0.56 (0.68%)

09/17/18
FBCO
09/17/18
NO CHANGE
Target $26
FBCO
Neutral
Teva price target raised to $26 from $23 at Credit Suisse
Credit Suisse analyst Vamil Divan reiterated a Neutral rating on Teva Pharmaceutical (TEVA) and raised his price target to $26 after the company said it received FDA approval for Ajovy, a key pipeline drug for migraine prevention and approval of a quarterly dosing for the drug, providing an important point of differentiation relative to competitors from Eli Lilly (LLY) and Amgen (AMGN)/Novartis (NVS). In a research note to investors, Divan says Friday's approval provides Teva with an important potential growth driver as it looks to overcome the challenges it faces with U.S. generics, Copaxone and its large debt load, and expects a "strong" positive reaction in the stock. Divan says he will look to see how Teva commercializes Ajovy in the coming months before becoming more constructive on the stock's longer-term outlook.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Novartis initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Novartis with a Neutral rating and CHF 94 price target, stating that its Alcon spin likely will generate value, but he believes additional pipeline catalysts are needed to drive operating leverage.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $50
PIPR
Overweight
Piper recommends Deciphera into systemic mastocytosis data
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Deciphera Pharmaceuticals (DCPH) with a $50 price target following a deep dive into the systemic mastocytosis treatment space and the potential for DCC-2618 to play a meaningful role in the disease. The analyst continues to recommend purchase of Deciphera into the systemic mastocytosis data for DCC-2618 early next year. Given what's been presented before between Novartis' (NVS) midostaurin and Blueprint Medicines' (BPMC) avapritinib, Raymond thinks an overall response rate of greater than 50% with a continued clean safety profile should be considered a win for DCC-2618. He models for DCC-2618 systemic mastocytosis revenue of $44M, $151M, and $290M for 2023 through 2025, respectively. The analyst remains a buyer of Deciphera shares into the Q1 of 2019 data.
PFE Pfizer
$43.78

0.97 (2.27%)

10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/01/18
JPMS
10/01/18
NO CHANGE
Target $46
JPMS
Overweight
Pfizer price target raised to $46 from $42 at JPMorgan
JPMorgan analyst Chris Schott raised his price target for Pfizer to $46 on a revisit of the company's story. The analyst sees a "meaningful shift" in the Pfizer narrative away from potential acquisitions to the company's organic growth prospects post the Lyrica patent expiration in 2019. While he expects the company's growth will slow in 2019/2020, he sees a "distinct re-acceleration" of sales and earnings growth for Pfizer in the 2021-2025 period. Schott believes shares of Pfizer can further re-rate if the Street gains further confidence in its "sustained topline growth and capital deployment opportunities." The analyst keeps an Overweight rating on the shares.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
09/18/18
JPMS
09/18/18
NO CHANGE
Target $81
JPMS
Overweight
Market evolving favorably for Ascendis into Phase III results, says JPMorgan
JPMorgan analyst Jessica Fye believes the long-acting growth hormone deficiency competitive landscape is evolving favorably for Ascendis Pharma heading into the Phase III results for the company's TransCon growth hormone in Q1 of 2019. The past 12-24 months has brought emerging clinical issues for all three of the key long-acting competitors, Fye tells investors in a research note. These range from the failure of Versartis (VSAR) at the most extreme, to the missed pivotal trial in adults for Pfizer (PFE) and Opko (OPK), to results that may raise questions around efficacy for Novo (NVO) in adults, Fye contends. The analyst believes these create opportunity for Ascendis, assuming the company is successful in Phase III. She continues to have high conviction in the success of the Phase III trial and keeps an Overweight rating on Ascendis Pharma with an $81 price target.
RHHBY Roche
$0.00

(0.00%)

09/21/18
PIPR
09/21/18
NO CHANGE
Target $400
PIPR
Overweight
Biogen upcoming BIIB098 data an overlooked catalyst, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes investor sentiment on Biogen (BIIB) overlooks the H2H tolerability data for BIIB098 versus Tecfidera coming in the first half of 2018 Though BIIB098 is largely discounted as an intellectual property play "or worse," the readout, if positive, may be an important catalyst ahead of FDA approval in Q4 of 2019, Raymond tells investors in a research note. He suspects that if BIIB098 shows meaningful tolerability improvement over Tecfidera, "docs will likely take notice." Further, Raymond's new neurologist survey indicates that while the launch trends of Roche's (RHHBY) multiple sclerosis drugOcrevus "appear to be improving," other share trends, including those for Tecfidera and Tysabri, "remain stable." The analyst keeps an Overweight rating on Biogen with a $400 price target.
10/03/18
PIPR
10/03/18
NO CHANGE
PIPR
Overweight
PTC, Roche data add uncertainty to Biogen drug outlook, says Piper Jaffray
The risdiplam spinal muscular atrophy data released this morning by PTC Therapeutic (PTCT) and Roche (RHHBY) stack up fairly well to Biogen's (BIIB) Spinraza clinical data, Piper Jaffray analyst Christopher Raymond tells investors in a research note. Even taking into account all of the usual caveats regarding cross-trial comparisons, risdiplam is shaping up well compared to Spinraza, the analyst contends. He sees the new data as adding uncertainty to the Spinraza trajectory. Nonetheless, Raymond keeps an Overweight rating on shares of Biogen. The analyst made no changes to his Biogen model, but he admits risdiplam, if the data holds up, may impact Spinraza's ultimate market potential. Biogen in midday trading is up 2% to $351.41.
10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
SNY Sanofi
$42.89

-0.83 (-1.90%)

10/11/18
PIPR
10/11/18
NO CHANGE
Target $450
PIPR
Overweight
Piper remains buyer of Regeneron ahead of October 20 FDA action date
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Regeneron Pharmaceuticals (REGN) ahead of the Dupixent asthma October 20 FDA action date. With consensus expecting this indication to contribute well over $1B in revenue in coming years, approval is a "critical near-term catalyst" for the shares, Raymond tells investors in a research note. The analyst adds that while some investors have expressed angst over the breadth of the label, namely restricting use to eosinophilic asthma, he believes recent Sanofi (SNY) commentary provides reason for optimism. The totality of clinical data and the biology behind Dupixent supports a broad label, Raymond contends. He maintains an Overweight rating on Regeneron with a $450 price target.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
Sanofi initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Sanofi with a Neutral rating and EUR83 price target. He sees its low earnings risk, strong dividend, and reasonable valuation being offset by competitive intensity building for Dupixent and its hemophilia franchises.
10/09/18
BARD
10/09/18
INITIATION
Target $50
BARD
Outperform
Principia Biopharma initiated with an Outperform at Baird
Baird analyst Brian Skorney started Principia Biopharma (PRNB) with an Outperform rating and $50 price target, stating that its BTK inhibitor partnered with Sanofi (SNY) for multiple sclerosis has blockbuster potential. He also believes PRN1008, which is entering Phase 3, has a worldwide opportunity over $500M in pemphigus that would also open the door for a host of other indications.
10/01/18
PIPR
10/01/18
NO CHANGE
PIPR
Overweight
Piper keeps Overweight on Regeneron after Libtayo approval
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Regeneron Pharmaceuticals (REGN) after Friday's FDA approval of Libtayo in cutaneous squamous cell carcinoma. Timing is about a month ahead of the late-October FDA action date for Regeneron/Sanofi's (SNY) PD-1 inhibitor, but a positive decision was expected given the drug's "compelling data" in advanced CSCC, Raymond tells investors in a research note. While Libtayo will enter the market as the sixth approved PD-(L)1 inhibitor and third approved PD-1 agent, Raymond thinks readouts from the ongoing development program in other indications such as first-line non-small-cell lung carcinoma may make the case for moderate Libtayo uptake. However, he continues to like the set-up for Regeneron shares going forward.
NYT New York Times
$24.98

0.145 (0.58%)

10/11/18
JPMS
10/11/18
NO CHANGE
Target $32
JPMS
Overweight
New York Times price target raised to $32 from $27 at JPMorgan
JPMorgan analyst Alexia Quadrani raised her price target for New York Times to $32 and reiterates an Overweight rating on the shares ahead of the company's Q3 results. The analyst says that while quarterly subscriber growth may continue to be volatile, the company's longer-term trends are positive. She expects New York Times' growth to "remain at elevated levels for the foreseeable future." Quadrani projects a ramp in digital subscriber growth in part driven by the Kavanaugh hearings, Trump tax stories, and midterm elections.
04/30/18
04/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Outperform from Sector Perform at RBC Capital with analyst Nik Modi saying while his concerns around the macro backdrop and fundamentals persist, the current valuation of 13-times forward PE is attractive relative to the broader Consumer Packaged Goods category given the company's potential catalysts of more dividend increases tracking higher interest rates and the FDA approval process for IQOS electronic cigarettes. 2. Aaron's (AAN) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying he remains "impressed" by Progressive's revenue growth and thinks the unit will benefit from Rent-A-Center's (RCII) "ongoing struggles." 3. Cirrus Logic (CRUS) upgraded to Buy from Hold at Craig-Hallum with analyst Anthony Stoss saying he believes Apple (AAPL) headwinds are already priced into the stock and a relief rally is likely following the company's upcoming earnings this Wednesday. 4. Ventas (VTR) upgraded to Market Perform from Underperform at BMO Capital with John Kim citing a more attractive valuation after the stock price came down another 19% in 2018. 5. New York Times (NYT) upgraded to Overweight from Neutral at JPMorgan with analyst Alexia Quadrani saying she believes digital demand will likely drive further "outsized growth" for New York Times. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/18
10/11/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN UPGRADES LUMENTUM AFTER SELLOFF: JPMorgan analyst Samik Chatterjee upgraded Lumentum (LITE) to Overweight from Neutral with an unchanged price target of $80. The 19% stock decline from the highs in late August, driven by concerns relative to U.S.-China trade, over-appreciates the "modest risks" for Lumentum, Chatterjee said. He believes this creates an "attractive buying opportunity" to capitalize on the near-term improvement in the earnings outlook. GOLDMAN CUTS HUNTINGTON TO SELL: Goldman Sachs analyst Noah Poponak downgraded Huntington Ingalls Industries (HII) to Sell from Neutral and lowered his price target for the shares to $208 from $220. Poponak said Huntington is now the most expensive stock in his Defense coverage on economic, price-to-earnings and free cash flow yield. The analyst believes the stock could underperform Defense peers in the medium-term given the valuation. JEFFRIES STARTS HERBALIFE WITH A BUY: Jefferies analyst Akshay Jagdale started Herbalife Nutrition (HLF) with a Buy rating and $65 price target. After a period of "muted growth," Herbalife's sales looked poised to accelerate to a more normalized range of 5%-9%, Jagdale believes. He thinks the company should be able to grow at least in line with its total addressable market growth rate of 6%. This, coupled with margin expansion and accretive free cash flow usage, should drive "significant" earnings upside and support a "growth company valuation," Jagdale said. JPMORGAN RAISES PRICE TARGET ON NY TIMES: JPMorgan analyst Alexia Quadrani raised her price target for New York Times (NYT) to $32 and reiterated an Overweight rating on the shares ahead of the company's Q3 results. The analyst said that while quarterly subscriber growth may continue to be volatile, the company's longer-term trends are positive. She expects New York Times' growth to "remain at elevated levels for the foreseeable future." SNAP PRICE TARGET CUT AT GOLDMAN SACHS: Goldman Sachs analyst Heath Terry lowered his price target for Snap (SNAP) to $11 from $17, while reiterating a Buy rating on the shares. With Snap shares down 50% since the company reported Q2 results, beyond the broader weakness in social media, the analyst believes investors are clearly focused on the impact competition is having on the company's user growth, ability to monetize, and capital needs. Terry continues to believe that a Twitter-like (TWTR) turnaround is possible, particularly as the new Android app comes out of Alpha later this quarter. However, it is unlikely that Q3 results will show any signs of that as reported DAUs decline and engagement is negatively impacted by the redesign/competition, he said.
04/30/18
JPMS
04/30/18
UPGRADE
Target $27
JPMS
Overweight
New York Times upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alexia Quadrani upgraded New York Times to Overweight and raised her price target for the shares to $27 from $25. The analyst believes digital demand will likely drive further "outsized growth" for New York Times. Further, she expects the company's earnings growth to accelerate in early 2019.
STMP Stamps.com
$214.32

-0.43 (-0.20%)

05/31/18
MAXM
05/31/18
INITIATION
Target $320
MAXM
Buy
Stamps.com initiated with a Buy at Maxim
Maxim initiated Stamps.com with a Buy and $320 price target.
06/01/18
06/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Hold at Needham. 2. Xenia Hotels (XHR) initiated with an Outperform at Baird. 3. Stamps.com (STMP) and Pitney Bowes (PBI) were initiated with a Buy at Maxim. 4. Getty Realty (GTY) initiated with a Buy at Ladenburg. 5. Dana (DAN) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/21/18
RILY
06/21/18
NO CHANGE
RILY
Any selloff in Stamps.com represents attractive buying opportunity, says B. Riley FBR
With Stamps.com trading down 12% intraday, B. Riley FBR analyst Kevin Liu reiterated his Buy rating and $300 price target, saying that any sell-off in Stamps.com represents an "attractive buying opportunity" given "the company's entrenched relationship with the USPS and strategic positioning in e-commerce." He added that Trump's proposal to privatize the Post Office, while it would present risks to the company, is still simply speculation at this point.
07/26/18
ROTH
07/26/18
NO CHANGE
Target $305
ROTH
Buy
Stamps.com price target raised to $305 from $255 at Roth Capital
Roth Capital analyst Darren Aftahi raised his price target for Stamps.com to $305 from $255 as he expects slightly above consensus results when the company reports Q2 results. His SHOP customer checks suggest 200bps improvement in Shipping penetration along with healthy merchant underlying business growth. This serves as one positive data point that gives the analyst comfort in his above consensus estimate. Aftahi reiterates a Buy rating on the shares.
AMZN Amazon.com
$1,788.63

69.51 (4.04%)

10/08/18
FBCO
10/08/18
NO CHANGE
FBCO
Amazon adds fire to already-challenging retail cost inflation situation, says Credit Suisse
Credit Suisse analyst Michael Binetti says that Amazon's comments that it plans to lobby the government for higher minimum wages could be a catalyst for broad-based ongoing cost inflation across the U.S. retail industry. The analyst estimates that, on average, every $1 increase in wage rates could be a 30bp drag to EBIT margins and about 4%-5% drag to annualized EPS growth for U.S. retailers. The retailers with most wage-related EPS risk have a combo of low labor costs/wage rates, closest to regional minimums today and already low margins, he contends. Further, Binetti believes that Amazon's wage raise announcement timing could mean pressure to retailers' EPS guidance as early as Q4.
10/12/18
STFL
10/12/18
NO CHANGE
Target $200
STFL
Buy
Stifel replaces Alibaba with Amazon on Select List after target drop
Stifel analyst Scott Devitt removed Alibaba (BABA) from his firm's Select List and replaced it with Amazon.com (AMZN). The analyst cites an "increasingly uncertain" China macro environment and near-term optimism for Amazon for the change. He also updated his Alibaba model, which resulted in near-term revenue growth assumptions that are 300 basis points lower versus his prior forecast. However, despite the difficult China market backdrop, Devitt continues to view Alibaba as a core long-term holding. He lowered his price target for the shares to $200 from $220 while keeping a Buy rating on the name.
10/08/18
FBCO
10/08/18
NO CHANGE
FBCO
Outperform
Global brand ranking validates Microsoft rebranding efforts, says Credit Suisse
Credit Suisse analyst Brad Zelnick notes that, among top global brands, Microsoft (MSFT) ranked fourth in global brand ranking with a brand value of $92.7B, superseded only by Amazon (AMZN), Google (GOOG; GOOGL) and Apple (AAPL). The analyst believes this validates Microsoft's rebranding efforts in the Satya era, distinguished by a more open and flexible approach to customers, rivals as well as application developers. Zelnick reiterates an Outperform rating on Microsoft shares.
10/12/18
TIGR
10/12/18
NO CHANGE
TIGR
Amazon pullback a buying opportunity, says Tigress Financial
Tigress Financial analyst Ivan Feinseth reiterated a Buy rating on Amazon.com, citing the company's leveraging of its retail, e-commerce, and web hosting platforms to develop new business lines and penetrate new markets. The analyst believes there is significant upside in the stock and views the recent pullback as a buying opportunity.

TODAY'S FREE FLY STORIES

22:20
10/18/18
10/18
22:20
10/18/18
22:20
General news
China's GDP slowed to a 6.5% y/y growth pace in Q3 »

China's GDP slowed…

NI

NiSource

$25.25

0.22 (0.88%)

21:12
10/18/18
10/18
21:12
10/18/18
21:12
Downgrade
NiSource rating change at Goldman Sachs »

NiSource downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

PNW

Pinnacle West

$83.48

-0.235 (-0.28%)

21:04
10/18/18
10/18
21:04
10/18/18
21:04
Upgrade
Pinnacle West rating change at Goldman Sachs »

Pinnacle West upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 11

    Nov

  • 11

    Nov

NVS

Novartis

$86.24

0.9 (1.05%)

20:26
10/18/18
10/18
20:26
10/18/18
20:26
Hot Stocks
Novartis granted orphan status for melanoma treatment »

The FDA granted Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 07

    Nov

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

, HON

Honeywell

$155.22

-2.73 (-1.73%)

20:25
10/18/18
10/18
20:25
10/18/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$80.31

-0.8628 (-1.06%)

HON

Honeywell

$155.22

-2.73 (-1.73%)

SLB

Schlumberger

$58.43

-0.81 (-1.37%)

VFC

VF Corp.

$87.07

-2.22 (-2.49%)

STT

State Street

$79.62

-2.5 (-3.04%)

STI

SunTrust

$61.46

-0.94 (-1.51%)

SYF

Synchrony

$29.63

-0.45 (-1.50%)

CFG

Citizens Financial

$34.92

-0.96 (-2.68%)

KSU

Kansas City Southern

$102.68

-1.31 (-1.26%)

IPG

Interpublic Group

$22.48

0.28 (1.26%)

EEFT

Euronet

$112.64

-2.96 (-2.56%)

MAN

Manpower

$78.38

-1.09 (-1.37%)

GNTX

Gentex

$18.62

-0.32 (-1.69%)

CLF

Cleveland-Cliffs

$11.47

-0.37 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 24

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 26

    Nov

  • 26

    Nov

  • 06

    Dec

  • 03

    Mar

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

20:24
10/18/18
10/18
20:24
10/18/18
20:24
Upgrade
Canadian Pacific rating change at National Bank »

Canadian Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

19:57
10/18/18
10/18
19:57
10/18/18
19:57
Hot Stocks
DowDuPont clarifies the charge is the result of previously reported conditions »

In response to market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

19:35
10/18/18
10/18
19:35
10/18/18
19:35
Downgrade
Valero Energy Partners rating change at RBC Capital »

Valero Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

IVZ

Invesco

$21.26

0.32 (1.53%)

19:33
10/18/18
10/18
19:33
10/18/18
19:33
Downgrade
Invesco rating change at Credit Suisse »

Invesco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

LOGC

LogicBio Therapeutics

$0.00

(0.00%)

19:31
10/18/18
10/18
19:31
10/18/18
19:31
Syndicate
LogicBio Therapeutics 7M share IPO priced at $10.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MDSO

Medidata

$70.91

1.54 (2.22%)

19:07
10/18/18
10/18
19:07
10/18/18
19:07
Recommendations
Medidata analyst commentary at JPMorgan »

Medidata price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSLA

Tesla

$263.85

-8.09 (-2.97%)

18:58
10/18/18
10/18
18:58
10/18/18
18:58
Periodicals
Tesla rolls out new Model 3 with 'mid-range' battery pack, Electrek reports »

Tesla today is rolling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Dec

SKX

Skechers

$26.05

-0.64 (-2.40%)

, PYPL

PayPal

$77.50

-2.61 (-3.26%)

18:51
10/18/18
10/18
18:51
10/18/18
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$26.05

-0.64 (-2.40%)

PYPL

PayPal

$77.50

-2.61 (-3.26%)

CE

Celanese

$97.01

-2.76 (-2.77%)

CP

Canadian Pacific

$199.27

-6.68 (-3.24%)

ISRG

Intuitive Surgical

$522.41

-20.44 (-3.77%)

AXP

American Express

$102.86

-1.53 (-1.47%)

ETFC

E-Trade

$48.89

-1.68 (-3.32%)

VLP

Valero Energy Partners

$39.94

0.5 (1.27%)

VLO

Valero

$103.31

-0.36 (-0.35%)

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

OZK

Bank OZK

$34.85

-1.57 (-4.31%)

LLNW

Limelight Networks

$5.07

0.12 (2.42%)

TEAM

Atlassian

$81.96

-1.67 (-2.00%)

AIG

AIG

$48.62

-0.99 (-2.00%)

SREV

ServiceSource

$2.60

-0.08 (-2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 25

    Oct

  • 29

    Oct

  • 29

    Oct

  • 05

    Nov

  • 07

    Nov

  • 13

    Nov

  • 13

    Nov

  • 26

    Nov

  • 05

    Dec

  • 06

    Dec

X

U.S. Steel

$27.91

-0.27 (-0.96%)

, AKS

AK Steel

$4.69

-0.115 (-2.39%)

18:47
10/18/18
10/18
18:47
10/18/18
18:47
Periodicals
U.S. requests WTO panel to examine metals tariffs retaliation, Reuters says »

The U.S. has asked the…

X

U.S. Steel

$27.91

-0.27 (-0.96%)

AKS

AK Steel

$4.69

-0.115 (-2.39%)

NUE

Nucor

$58.26

-0.85 (-1.44%)

STLD

Steel Dynamics

$41.32

0.77 (1.90%)

AA

Alcoa

$38.85

2.14 (5.83%)

CENX

Century Aluminum

$9.91

-0.23 (-2.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 25

    Oct

  • 26

    Oct

  • 02

    Nov

RLH

Red Lion Hotels

$12.62

-0.42 (-3.22%)

18:43
10/18/18
10/18
18:43
10/18/18
18:43
Hot Stocks
Red Lion Hotels CFO Douglas Ludwig resigns due to personal health reasons »

RLH Corporation announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

IDA

IDACORP

$96.78

0.035 (0.04%)

18:30
10/18/18
10/18
18:30
10/18/18
18:30
Hot Stocks
IDACORP declares quarterly dividend of 63c per share »

Director of IDACORP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$20.70

-0.59 (-2.77%)

18:08
10/18/18
10/18
18:08
10/18/18
18:08
Syndicate
Krystal Biotech 3M share Secondary priced at $20.00 per share »

Cowen, William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 19

    Oct

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

, SVU

Supervalu

$32.49

0.02 (0.06%)

18:05
10/18/18
10/18
18:05
10/18/18
18:05
Hot Stocks
S&P announces changes to S&P SmallCap 600 index »

S&P Dow Jones Indices…

FBC

Flagstar Bancorp

$29.26

-0.33 (-1.12%)

SVU

Supervalu

$32.49

0.02 (0.06%)

UNFI

United Natural Foods

$26.94

0.2 (0.75%)

TTGT

TechTarget

$19.53

-0.35 (-1.76%)

PERY

Perry Ellis

$27.48

0.02 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 28

    Oct

  • 07

    Nov

  • 05

    Dec

  • 06

    Dec

  • 03

    Mar

SXT

Sensient

$76.67

-1.15 (-1.48%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
Sensient raises quarterly dividend to 36c from 33c per share »

The cash dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

DWDP

DowDuPont

$58.60

-0.98 (-1.64%)

18:02
10/18/18
10/18
18:02
10/18/18
18:02
Hot Stocks
DowDuPont says Sept. quarter results won't be impacted by $4.5B goodwill charge »

On October 18, 2018, E.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOG

Northern Oil and Gas

$3.54

-0.13 (-3.54%)

17:55
10/18/18
10/18
17:55
10/18/18
17:55
Hot Stocks
Northern Oil and Gas sees Q4 production 58% greater than Q2 »

Liquidity has increased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

SHPG

Shire

$176.90

-0.4 (-0.23%)

17:47
10/18/18
10/18
17:47
10/18/18
17:47
Hot Stocks
FDA advisory committee recommends Shire's Prucalopride for CIC »

Shire announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 21

    Dec

ACN

Accenture

$156.20

-2.76 (-1.74%)

, T

AT&T

$32.50

-0.06 (-0.18%)

17:37
10/18/18
10/18
17:37
10/18/18
17:37
Hot Stocks
CACI, IBM, Northrop Grumman and more compete for orders on $37.4B Army contract »

Accenture Federal…

ACN

Accenture

$156.20

-2.76 (-1.74%)

T

AT&T

$32.50

-0.06 (-0.18%)

CACI

CACI

$181.34

-2.07 (-1.13%)

HII

Huntington Ingalls

$233.27

0.15 (0.06%)

CMTL

Comtech

$32.05

-0.95 (-2.88%)

IBM

IBM

$130.52

-3.53 (-2.63%)

JEC

Jacobs Engineering

$73.01

-0.89 (-1.20%)

KFRC

Kforce

$35.15

-0.49 (-1.37%)

LLL

L3 Technologies

$218.17

-1.965 (-0.89%)

LDOS

Leidos

$66.72

-0.97 (-1.43%)

NOC

Northrop Grumman

$308.21

-1.04 (-0.34%)

RTN

Raytheon

$191.62

-1.48 (-0.77%)

KEYW

KEYW

$8.31

-0.27 (-3.15%)

VSEC

VSE Corp.

$30.75

-1.13 (-3.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 03

    Mar

UBSFY

Ubisoft

$0.00

(0.00%)

, BBY

Best Buy

$72.63

-1.2 (-1.63%)

17:31
10/18/18
10/18
17:31
10/18/18
17:31
Periodicals
Certain boxes of new Ubisoft game from Best Buy didn't include game, Kotaku says »

A number of Best Buy…

UBSFY

Ubisoft

$0.00

(0.00%)

BBY

Best Buy

$72.63

-1.2 (-1.63%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

AXP

American Express

$102.86

-1.53 (-1.47%)

17:28
10/18/18
10/18
17:28
10/18/18
17:28
Hot Stocks
American Express says revenue growth 'directly' linked to company decisions »

Says revenue growth has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 05

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.